Literature DB >> 9651802

Neuron degeneration induced by verapamil and attenuated by EGb761.

L Zhu1, J Gao, Y Wang, X N Zhao, Z X Zhang.   

Abstract

Calcium channel blockers are used as neuroprotective agents, as glutamate antagonists. However, it has been found that calcium channel blockers may compromise neuronal survival after long-term exposure. To explore the mechanisms of the toxicity of calcium channel blockers on neurons, we studied the morphological characteristics and biochemical changes of cultured cortical neurons treated with verapamil, a calcium channel blocker. We now report that cerebral cortical cultures exposed to verapamil for 48 h undergo neuronal degeneration in both concentration-dependent and time-dependent fashion, possibly partially through the activation of apoptosis. On the other hand, it was found that Ginkgo biloba extract (EGb761) attenuated verapamil-induced neuronal injury, suggesting the possibility of using verapamil combined with EGb761 clinically. Furthermore, both B-50 immunoactivity (BIA) and the concentration of intracellular calcium in single neurons ([Ca2+]i) decreased after a 48-h exposure to verapamil, suggesting that the mechanisms of verapamil-induced degeneration may be associated with the disruption of intracellular calcium homeostasis and the inhibition of normal axonal elongation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9651802     DOI: 10.1515/jbcpp.1997.8.4.301

Source DB:  PubMed          Journal:  J Basic Clin Physiol Pharmacol        ISSN: 0792-6855


  2 in total

Review 1.  Neuroprotective and Antioxidant Effect of Ginkgo biloba Extract Against AD and Other Neurological Disorders.

Authors:  Sandeep Kumar Singh; Saurabh Srivastav; Rudolph J Castellani; Germán Plascencia-Villa; George Perry
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

2.  Antiapoptotic Effects of EGb 761.

Authors:  Norma Serrano-García; José Pedraza-Chaverri; José Juan Mares-Sámano; Marisol Orozco-Ibarra; Arturo Cruz-Salgado; Anabel Jiménez-Anguiano; Julio Sotelo; Cristina Trejo-Solís
Journal:  Evid Based Complement Alternat Med       Date:  2013-07-29       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.